These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 33866376)

  • 1. Modified Glasgow Prognostic Score is predictive of prognosis for non-small cell lung cancer patients treated with stereotactic body radiation therapy: a retrospective study.
    Chen Z; Nonaka H; Onishi H; Nakatani E; Sato Y; Funayama S; Watanabe H; Komiyama T; Kuriyama K; Marino K; Aoki S; Araya M; Tominaga L; Saito R; Maehata Y; Oguri M; Saito M
    J Radiat Res; 2021 May; 62(3):457-464. PubMed ID: 33866376
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pretreatment Modified Glasgow Prognostic Score Predicts Clinical Outcomes After Stereotactic Body Radiation Therapy for Early-Stage Non-Small Cell Lung Cancer.
    Kishi T; Matsuo Y; Ueki N; Iizuka Y; Nakamura A; Sakanaka K; Mizowaki T; Hiraoka M
    Int J Radiat Oncol Biol Phys; 2015 Jul; 92(3):619-26. PubMed ID: 26068494
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic value of modified Glasgow Prognostic Score in non-muscle-invasive bladder cancer.
    Kimura S; D' Andrea D; Soria F; Foerster B; Abufaraj M; Vartolomei MD; Iwata T; Karakiewicz PI; Rink M; Gust KM; Egawa S; Shariat SF
    Urol Oncol; 2019 Mar; 37(3):179.e19-179.e28. PubMed ID: 30580906
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic index score predicts outcome of patients with Stage I non-small cell lung cancer after stereotactic body radiation therapy.
    Shi S; Ye L; Zhao Q; Hu Y; Huang Y; Chen G; Zeng Z; He J
    Jpn J Clin Oncol; 2019 Apr; 49(4):367-372. PubMed ID: 30715411
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prior Treatment for Non-small Cell Lung Cancer Is Associated With Improved Survival in Patients who Undergo Definitive Stereotactic Body Radiation Therapy for a Subsequent Lung Malignancy: A Retrospective Multivariate and Matched Pair Analysis.
    Farrugia MK; Jun Ma S; Hennon MW; Nwogu CE; Dexter EU; Picone AL; Demmy TL; Gomez-Suescun JA; Fung-Kee-Fung S; Yendamuri SS; Singh AK
    Am J Clin Oncol; 2021 Jan; 44(1):18-23. PubMed ID: 33264123
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Response criteria in solid tumors (PERCIST/RECIST) and SUV
    Pierson C; Grinchak T; Sokolovic C; Holland B; Parent T; Bowling M; Arastu H; Walker P; Ju A
    Radiat Oncol; 2018 Feb; 13(1):34. PubMed ID: 29486779
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predicting 5-Year Progression and Survival Outcomes for Early Stage Non-small Cell Lung Cancer Treated with Stereotactic Ablative Radiation Therapy: Development and Validation of Robust Prognostic Nomograms.
    Kang J; Ning MS; Feng H; Li H; Bahig H; Brooks ED; Welsh JW; Ye R; Miao H; Chang JY
    Int J Radiat Oncol Biol Phys; 2020 Jan; 106(1):90-99. PubMed ID: 31586665
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comprehensive analysis of Glasgow Prognostic Score (GPS)/the modified Glasgow Prognostic Score (mGPS) on immune checkpoint inhibitor efficacy among patients with advanced cancer.
    Zhang Y; Chen S; Chen H; Li W
    Cancer Med; 2023 Jan; 12(1):38-48. PubMed ID: 35702873
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pretreatment
    Satoh Y; Motosugi U; Saito A; Omiya Y; Onishi H
    Technol Cancer Res Treat; 2018 Jan; 17():1533033818794934. PubMed ID: 30222060
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Effect of Biologically Effective Dose and Radiation Treatment Schedule on Overall Survival in Stage I Non-Small Cell Lung Cancer Patients Treated With Stereotactic Body Radiation Therapy.
    Stahl JM; Ross R; Harder EM; Mancini BR; Soulos PR; Finkelstein SE; Shafman TD; Dosoretz AP; Evans SB; Husain ZA; Yu JB; Gross CP; Decker RH
    Int J Radiat Oncol Biol Phys; 2016 Dec; 96(5):1011-1020. PubMed ID: 27869080
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stereotactic body radiotherapy improves the survival of patients with oligometastatic non-small cell lung cancer.
    Ouyang W; Yu J; Nuerjiang S; Li Z; Wang D; Wang X; Zhang J; Xie C
    Cancer Med; 2019 Aug; 8(10):4605-4614. PubMed ID: 31245933
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the Glasgow Prognostic Score (GPS) and the modified Glasgow Prognostic Score (mGPS) in evaluating the prognosis of patients with operable and inoperable non-small cell lung cancer.
    Fan H; Shao ZY; Xiao YY; Xie ZH; Chen W; Xie H; Qin GY; Zhao NQ
    J Cancer Res Clin Oncol; 2016 Jun; 142(6):1285-97. PubMed ID: 26864695
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modified Glasgow Prognostic Score as a Prognostic Factor in Patients with Extensive Disease-Small-Cell Lung Cancer: A Retrospective Study in a Single Institute.
    Sonehara K; Tateishi K; Komatsu M; Yamamoto H; Hanaoka M; Kanda S; Koizumi T
    Chemotherapy; 2019; 64(3):129-137. PubMed ID: 31622969
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lung stereotactic body radiation therapy for elderly patients aged ≥ 80 years with pathologically proven early-stage non-small cell lung cancer: a retrospective cohort study.
    Watanabe K; Katsui K; Sugiyama S; Yoshio K; Kuroda M; Hiraki T; Kiura K; Maeda Y; Toyooka S; Kanazawa S
    Radiat Oncol; 2021 Feb; 16(1):39. PubMed ID: 33622369
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stereotactic body radiotherapy with adjuvant systemic therapy for early-stage non-small cell lung carcinoma: A multi-institutional analysis.
    Kann BH; Miccio JA; Stahl JM; Ross R; Verma V; Dosoretz AP; Park HS; Shafman TD; Gross CP; Yu JB; Decker RH
    Radiother Oncol; 2019 Mar; 132():188-196. PubMed ID: 30391106
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nomograms for predicting disease progression in patients of Stage I non-small cell lung cancer treated with stereotactic body radiotherapy.
    Ye L; Shi S; Zeng Z; Huang Y; Hu Y; He J
    Jpn J Clin Oncol; 2018 Feb; 48(2):160-166. PubMed ID: 29253245
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic value of modified Glasgow prognostic score in recurrent high-grade glial tumors treated with systemic treatment.
    Alan O; Telli TA; Basoğlu T; Arikan R; Demircan NC; Ercelep O; Bozkurt S; Atasoy BM; Dane F; Yumuk PF
    Clin Neurol Neurosurg; 2020 Sep; 196():105976. PubMed ID: 32531614
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Late metastatic presentation is associated with improved survival and delayed wide-spread progression after ablative stereotactic body radiotherapy for oligometastasis.
    Chen X; Chen H; Poon I; Erler D; Badellino S; Biswas T; Dagan R; Foote M; Louie AV; Ricardi U; Sahgal A; Redmond KJ
    Cancer Med; 2021 Sep; 10(18):6189-6198. PubMed ID: 34432390
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The preoperative sensitive-modified Glasgow prognostic score is superior to the modified Glasgow prognostic score in predicting long-term survival for esophageal squamous cell carcinoma.
    Tian R; Zhang F; Sun P; Wu J; Yan H; Wu AR; Zhang M; Jiang YL; Lu YH; Xu QY; Zhan XH; Zhang RX; Qian LT; He J
    Oncotarget; 2016 Oct; 7(41):67485-67494. PubMed ID: 27528228
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modified Glasgow Prognostic Score at Recurrence Predicts Poor Survival in Resected Non-Small Cell Lung Cancer (NSCLC) Patients.
    Lv Y; Pan Y; Dong C; Liu P; Zhang C; Xing D
    Med Sci Monit; 2017 Aug; 23():3780-3788. PubMed ID: 28775246
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.